Table 2—

Crude and adjusted relative risk(RR) of any cataract for the mean daily dose of inhaled (ICS) and nasal corticosteroid (NCS) in the 4-yr period prior to the index date

CasesControlsCrude RRAdjusted# RR (95% CI)
Subjects n27708110832
ICS dose μg·day−1342.1±476.1299.0±448.51.241.19 (1.15–1.23)
Range (mean) of ICS dose+ n
 0 (0)μg·day−110176456621.01.0 (reference)
 >0–500 (196)μg·day−110199396001.171.11 (1.07–1.14)
 >500–1000 (734)μg·day−14341158551.261.18 (1.13–1.35)
 >1000–1500 (1205)μg·day−1198766681.381.27 (1.20–1.40)
 >1500–2000 (1701)μg·day−178823701.551.44 (1.31–1.57)
 >2000 (2458)μg·day−12176771.501.36 (1.16–1.59)
NCS dose μg·day−117.3±57.214.1±51.21.111.08 (1.05–1.10)
Range (mean) of NCS dose+ n
 0 (0)μg·day−121556902651.01.0 (reference)
 >0–100 (34)μg·day−14649157141.241.16 (1.12–1.21)
 >100–200 (141)μg·day−189328611.311.21 (1.12–1.31)
 >200 (316)μg·day−161019921.281.18 (1.07–1.30)
  • Data are presented as mean±sd or absolute values. CI: confidence interval. #: for all factors in table 1, as well as the cumulative dose of the other class of topical corticosteroids; : per additional 1,000 μg·day−1 ICS or 100 μg·day−1 NCS (beclomethasone equivalents); +: among controls in category in beclomethasone equivalents.